Who owns ABEONA THERAPEUTICS INC. (ABEO)? Elite investor 13F holders
2 tracked elite investors reported holding ABEONA THERAPEUTICS INC as of 2026-09-30, including Rubric Capital, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Rubric Capital | ABEONA THERAPEUTICS INC | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 17533462.00 USD | 3339707.000000 | Shares | add | Original filing |
| D.E. Shaw | ABEONA THERAPEUTICS INC | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 61016.00 USD | 11622.000000 | Shares | reduce | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.